Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

O-002

Supelco

Oxycodone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill) :
C18H21NO4
Numéro CAS:
Poids moléculaire :
315.36
Numéro CE :
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24
Le tarif et la disponibilité ne sont pas disponibles actuellement.

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

COc1ccc2C[C@H]3N(C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O

InChI

1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1

Clé InChI

BRUQQQPBMZOVGD-XFKAJCMBSA-N

Informations sur le gène

human ... OPRM1(4988)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This Certified Spiking Solution® is suitable for numerous applications in GC/MS or LC/MS testing of oxycodone from clinical toxicology and urine drug testing to forensic analysis. Oxycodone is a semi-synthetic opioid analgesic sold under many trade names including OxyContin® and Percocet® for treatment of moderate to severe pain. Oxycodone is also sold illicitly under street names such as "Roxies," "Blues," and "Perks".

Produits recommandés

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
OxyContin is a registered trademark of Purdue Pharma L.P.
Percocet is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Prescrire international, 22(134), 10-11 (2013-02-02)
At high doses of oxycodone, the fixed-dose combination of oxycodone plus naloxone complicates therapeutic management and will likely have lower analgesic efficacy.
Raymond E Glazier et al.
Disability and health journal, 6(2), 107-115 (2013-03-20)
Substance abuse (SA) is a grave and pervasive social problem associated with severe personal and social costs that affect persons with disabilities disproportionally. Most previous research has found SA prevalence to be greater among persons with disabilities than among those
Reply to commentary.
Stephen F Butler
The journal of pain : official journal of the American Pain Society, 14(4), 361-362 (2013-04-04)
FDA ban of generic oxycodone calls into question Health Canada's approval.
Adam Miller
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 185(9), E381-E382 (2013-05-01)
Myoung Kim et al.
Journal of opioid management, 9(3), 189-204 (2013-06-19)
This article describes the rationale and design of the Oxycodone Users Registry (OUR) study and lessons learned during study development and data collection. The OUR study used a prospective registry design. Sixty-five academic and private medical practices across the United

Articles

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique